Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep. 2023;13(1):15922.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Elenjickal EJ, Travlos CK, Luu J, Lemay S, Suri RS, Mavrakanas TA. Efficacy and safety of SGLT-2 inhibitors in patients with and without advanced CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2025;20(6):788–809.

Devineni D, Polidori D. Clinical pharmacokinetic, pharmacodynamic, and drug–drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2015;54(10):1027–41.

Article  PubMed  CAS  Google Scholar 

Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087–97.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Carbone S, Dixon DL. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18(1):64.

Article  PubMed  PubMed Central  Google Scholar 

Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684–701.

Article  PubMed  Google Scholar 

Mavrakanas TA, Marsot A, Tsirella E, Rios N, Gritsas A, Suri RS. Canagliflozin pharmacokinetics at steady state in patients on maintenance hemodialysis. Kidney Int Rep. 2024;9(10):3049–52.

Article  PubMed  PubMed Central  Google Scholar 

Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37(3):610-28.e4.

Article  PubMed  CAS  Google Scholar 

Francke S, Mamidi RN, Solanki B, Scheers E, Jadwin A, Favis R, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061–72.

Article  PubMed  CAS  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

Article  PubMed  CAS  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

Article  PubMed  CAS  Google Scholar 

(FDA) AUSFaDA. T INVOKANA (canagliflozin) tablets—FDA prescribing information. 2023 [cited; Available from: U https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204042s040lbl.pdf.

Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231–44.

Article  PubMed  CAS  Google Scholar 

Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Carroll AK, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes Obes Metab. 2021;23(12):2632–42.

Article  PubMed  CAS  Google Scholar 

Dias BCL, Fachi MM, de Campos ML, Degaut FLD, Peccinini RG, Pontarolo R. A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. Biomed Chromatogr. 2019;33(11):e4663.

Article  PubMed  CAS  Google Scholar 

Baron KT, Macha S, Broedl UC, Nock V, Retlich S, Riggs M. Population pharmacokinetics and exposure-response (efficacy and safety/tolerability) of empagliflozin in patients with type 2 diabetes. Diabetes Ther. 2016;7(3):455–71.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fediuk DJ, Zhou S, Dawra VK, Sahasrabudhe V, Sweeney K. Population pharmacokinetic model for ertugliflozin in healthy subjects and patients with type 2 diabetes mellitus. Clin Pharmacol Drug Dev. 2021;10(7):696–706.

Article  PubMed  CAS  Google Scholar 

Riggs MM, Staab A, Seman L, MacGregor TR, Bergsma TT, Gastonguay MR, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol. 2013;53(10):1028–38.

Article  PubMed  CAS  Google Scholar 

van der Aart-van der Beek AB, Koomen JV, Dekkers CCJ, Barbour SJ, Boulton DW, Gansevoort RT, et al. Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease. Clin Pharmacokinet. 2021;60(4):517–25.

Article  PubMed  PubMed Central  Google Scholar 

van der Walt J-S, Hong Y, Zhang L, Pfister M, Boulton D, Karlsson M. A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-O-glucuronide in renal or hepatic impairment. CPT Pharmacomet Syst Pharmacol. 2013;2(5):42.

Google Scholar 

Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A. Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2016;55(2):209–23.

Article  PubMed  CAS  Google Scholar 

Penland RC, Melin J, Boulton DW, Tang W. Evaluation of the pharmacokinetics of dapagliflozin in patients with chronic kidney disease with or without type 2 diabetes mellitus. J Clin Pharmacol. 2023;63(5):551–9.

Article  PubMed  CAS  Google Scholar 

Soenen S, Rayner CK, Horowitz M, Jones KL. Gastric emptying in the elderly. Clin Geriatr Med. 2015;31(3):339–53.

Article  PubMed  Google Scholar 

O’Mahony D, O’Leary P, Quigley EMM. Aging and intestinal motility. Drugs Aging. 2002;19(7):515–27.

Article  PubMed  Google Scholar 

Castleden CM, Volans CN, Raymond K. The effect of ageing on drug absorption from the gut. Age Ageing. 1977;6(3):138–43.

Article  PubMed  CAS  Google Scholar 

Mallet L. Pharmacology of drugs in aging. In: Huang AR, Mallet L, editors. Medication-related falls in older people: causative factors and management strategies. Cham: Springer International Publishing; 2016. p. 55–66.

Chapter  Google Scholar 

Drenth-van Maanen AC, Wilting I, Jansen PAF. Prescribing medicines to older people—how to consider the impact of ageing on human organ and body functions. Br J Clin Pharmacol. 2020;86(10):1921–30.

Article  PubMed  Google Scholar 

Brown NA, Levine JL, Zenilman ME. Age-related changes in the gastrointestinal tract. In: Rosenthal RA, Zenilman ME, Katlic MR, editors. Principles and practice of geriatric surgery. New York: Springer New York; 2011. p. 711–27.

Chapter  Google Scholar 

Iijima H, Kifuji T, Maruyama N, Inagaki N. Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther. 2015;32:768–82.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pollack R, Cahn A. Sglt2 inhibitors and safety in older patients. Heart Fail Clin. 2022;18(4):635–43.

Article  PubMed  Google Scholar 

Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study. Diabetes Care. 2019;43(2):468–75.

Article  PubMed  Google Scholar 

Evelo A, Leegwater E, Visser LE. Sex differences in pharmacokinetics, pharmacodynamics, and adverse drug reactions of cardiovascular drugs. In: Maas AHEM, Gerdts E, editors. Manual of cardiovascular disease in women. Cham: Springer Nature Switzerland; 2024. p. 445–59.

Chapter  Google Scholar 

Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42(2):107–21.

Article  PubMed  CAS  Google Scholar 

Valentine V, Hinnen D. Clinical implications of canagliflozin treatment in patients with type 2 diabetes. Clin Dia